<DOC>
	<DOCNO>NCT01930006</DOCNO>
	<brief_summary>In study two MGCD265 oral formulation dose level 100 mg administer healthy male female subject fast condition .</brief_summary>
	<brief_title>Safety Study Two Oral Formulations MGCD265 Administered Healthy Subjects Fasting State</brief_title>
	<detailed_description>The objective study compare rate extent absorption two MGCD265 oral formulation dose level 100 mg administer healthy male female subject fast condition .</detailed_description>
	<criteria>1 . Healthy male female subject ≥18 ≤55 year age willing able provide inform consent prior perform study relate procedure 2 . Females childbearing potential use stable contraceptive method least 30 day prior screen willing use one follow acceptable birth control method 30 day last dose study drug : 1 . Abstinence 2 . Hormonal contraceptive ( birth control pill , injectable/ implantable/ insertable hormonal birth control product , transdermal patch ) least 3 month prior first dose study drug male condom intravaginal spermicide 3 . Intrauterine contraceptive device ( IUD ) place least 3 month prior first dose study drug plus spermicide male condom 4 . Male condom diaphragm plus spermicide ; 5 . Male condom cervical cap plus spermicide ; 6 . Surgical sterilization partner ( ) ( vasectomy 6 month minimum prior first dose study drug ) 3 . Female subject consider non childbearing potential eligible one follow condition meet : 1 . Amenorrhea least 1 year , confirmation folliclestimulating hormone ( FSH ≥ 40 mIU/mL ) 2 . Hysterectomy 3 . Bilateral oophorectomy 4 . Bilateral tubal ligation 4 . Male subject must agree abstinent use follow acceptable contraception method collaboration female partner time take first dose 3 month last dose study drug : 1 . Male condom intravaginal spermicide plus hormonal contraceptive ( birth control pill , injectable/ implantable/ insertable hormonal birth control product , transdermal patch ) use least 3 month 2 . Male condom IUD place least 3 month plus spermicide ; 3 . Male condom diaphragm plus spermicide 4 . Male condom cervical cap plus spermicide 5 . Vasectomy 6 month minimum prior first dose study drug Male subject also agree donate sperm time take first dose study drug 3 month last dose study drug 5 . Subject body mass index ( BMI ) 18.0 32.0 kg/m2 screen 6 . Subject current nonsmoker use nicotine contain product within 3 month prior screen 7 . Subjects consider generally healthy upon completion medical history , physical examination , vital sign , screen laboratory result screen ECG judge investigator 8 . Subjects willing able comply visit schedule , treatment plan , laboratory test , pharmacokinetic sampling schedule study procedures 1 . Females pregnant breast feed 2 . History significant hypersensitivity reaction substance drug 3 . Clinically relevant history evidence significant gastrointestinal , hepatic , renal , endocrine , pulmonary , neurological , psychiatric , cardiovascular , hematologic , dermatologic , immunologic disease condition know interfere absorption , distribution , metabolism distribution drug opinion investigator would jeopardize safety subject impact validity study result 4 . Clinically significant vital sign opinion investigator screen prior study drug administration 5 . History clinically significant cardiovascular illness include confine : angina pectoris myocardial infarction , coronary peripheral artery bypass graft , congestive heart failure , clinically significant cardiac arrhythmia opinion investigator 6 . History clinically significant thrombotic hemorrhagic event ( include confine stroke transient ischemic attack ) ; history bleed diathesis coagulopathy ; history presence gastrointestinal condition risk perforation ; presence nonhealing wound , ulcer fracture opinion investigator 7 . Presence outofrange cardiac interval ( PR &lt; 110 msec , PR &gt; 200 msec , QRS &lt; 60 msec , QRS &gt; 110 msec QTcF &gt; 450 msec ) screen predose ECG clinically significant ECG abnormality opinion investigator 8 . History regular alcohol consumption exceed 7 drink female 14 drink per week male within 6 month screen positive alcohol breath test screen prior study drug administration 9 . History significant drug abuse within one year prior screen 10 . Any clinically significant illness surgery previous 30 day day 1 study 11 . Use enzymemodifying drug , include strong inhibitor cytochrome P450 ( CYP ) enzymes ( cimetidine , fluoxetine , quinidine , erythromycin , ciprofloxacin , fluconazole , ketoconazole , diltiazem HIV antiviral ) strong inducer CYP enzyme ( barbiturate , carbamazepine , glucocorticoid , phenytoin , rifampin St John 's Wort ) , previous 30 day day 1 study 12 . Use drug know induce inhibit hepatic metabolism ( inducer rifampin , barbiturate , carbamazepine , phenytoin , glucocorticoid , omeprazole ; inhibitor antidepressant ( SSRI ) , cimetidine , diltiazem , macrolides , imidazole , neuroleptic , verapamil , fluroquinolones , antihistamine ) previous 30 day day 1 study 13 . Use prescription medication previous 14 day day 1 study 14 . Use overthecounter ( OTC ) product include cold preparation , multivitamin dietary supplement use therapeutic benefit antacid preparation previous 7 day day 1 study 15 . Use Acetylsalicylic Acid ( ASA ) NSAIDs ( product contain ASA NSAIDs ) previous 7 day day 1 study 16 . Use MAO inhibitor within 30 day day 1 study 17 . Positive urine drug screen urine cotinine test screen prior study drug administration 18 . Positive result HIV , HBsAg antiHCV test screen 19 . Subjects take Investigational Product ( another clinical trial ) previous 30 day ( 90 day biologics ) day 1 study 20 . Donation plasma within 7 day prior dose . Any donation/loss blood blood product within 3 month screen visit 21 . Prior exposure MGCD265 No subject allow enroll study ( i.e . study conduct 1 group ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>c-Met</keyword>
	<keyword>VEGFR</keyword>
	<keyword>Ron</keyword>
	<keyword>Cancer</keyword>
	<keyword>Tumor</keyword>
	<keyword>Safety</keyword>
	<keyword>Phase 1</keyword>
</DOC>